$EXEL

Beckerle Mary C sold $527K of EXEL

Beckerle Mary C sold 9,812 shares of EXELIXIS, INC. (EXEL) at $53.66 ($0.53M total) on 2026-08-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Beckerle Mary C
Published Aug 12, 2026, 11:34 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 12, 2026, 11:41 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$EXEL
Neutral
high confidence
Mentioned
$EXEL
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EXELNeutralLow
01

Why it matters

The newest fact is the specific sale size, price, and that it was executed under a pre-arranged 10b5-1 plan; it does not include any new guidance, trial result, deal, or regulatory action.

02

Market read

Traders may note the insider sale, but the 10b5-1 structure and lack of fundamental updates make it unlikely to drive a meaningful repricing by itself.

03

What to watch

The filing does not indicate whether the director’s broader selling program is complete, nor does it provide context on total holdings changes beyond the post-transaction share count.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-12 after the 2026-08-10 sale

Background

The article is an SEC Form 4 insider transaction disclosure for EXELIXIS, Inc. (EXEL).

Company-level read

Ticker impact

$EXELNeutralHigh confidence
Context

EXELIXIS director Beckerle Mary C sold 9,812 shares at $53.66 on 2026-08-10 under a 10b5-1 plan, totaling about $526.5K.

Expected impact

Low likelihood of a sustained price move driven by this filing alone.

Evidence & confidence

The disclosure is an open-market sale by a director, explicitly tied to a Rule 10b5-1 plan, and provides no new company-specific operational or financial information.

Market effects

No clear sector read-through from a single director 10b5-1 sale.

None.

None.

Counterpoint

Insider sales can still reflect private risk perceptions, even when executed under 10b5-1, especially if multiple sales cluster over time.

Key entities

  • EXELIXIS, INC.

    Company whose director insider sale is disclosed on SEC Form 4.

  • Beckerle Mary C

    Director who sold 9,812 shares at $53.66 under a Rule 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$EXELHigh

EXELIXIS, INC. (EXEL): Results of Operations and Financial Condition

EXELIXIS, INC. (EXEL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 5 exel20260630exhibit991.htm EX-99.1 Document Exhibit 99.1 Contacts: Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 csenner@exelixis.com Andrew Peters SVP, Strategy & Investor Relations Exelixis, Inc. 650-837-7248 apeters@exelixis.com Exelixis Announces

$EXELMed

EXEL Industries: Q3 2025-2026 revenue -18.7%

EXEL Industries reported Q3 FY2025-2026 revenue of €229.2m, down 18.7% year on year, or -18.0% at constant FX and scope, citing lower agricultural equipment volumes. Agricultural Spraying fell 17.1%, Sugar Beet Harvesting 35.6%, Leisure 14.2%, and Industry 16.7%. The company expects no significant cycle recovery before H2 FY2026-2027.

$EXELMedAI 9/10

If Decades of History Tell Us Anything, This Biotech Near $50 Is Primed to Skyrocket

Exelixis reported Q1 2026 results that beat consensus, with non-GAAP EPS of $0.87 (up 14.02% vs. expectations) on revenue of $610.81 million (up 9.97% YoY). The company said CABOMETYX franchise revenue rose 12.5% YoY to $764 million and authorized a $750 million buyback through Dec. 31, 2027. Exelixis also has a Dec. 3, 2026 PDUFA decision for zanzalintinib in metastatic colorectal cancer.